NFKB1 and breast carcinoma: Owing to the cross-talk between NF-kB and ROS/JNK axis, the ability of APE to simultaneously activate ROS/JNK proapoptotic pathway and inhibit ROS/NF-kB anti-apoptotic pathway might provide a powerful new adjuvant for breast cancer treatment.